JOP20190008A1 - علاج ومنع اضطرابات النوم - Google Patents

علاج ومنع اضطرابات النوم

Info

Publication number
JOP20190008A1
JOP20190008A1 JOP/2019/0008A JOP20190008A JOP20190008A1 JO P20190008 A1 JOP20190008 A1 JO P20190008A1 JO P20190008 A JOP20190008 A JO P20190008A JO P20190008 A1 JOP20190008 A1 JO P20190008A1
Authority
JO
Jordan
Prior art keywords
strong
treatment
prevention
animal
compound
Prior art date
Application number
JOP/2019/0008A
Other languages
English (en)
Inventor
Garth Whiteside
Donald J Kyle
Stephen C Harris
Ram P Kapil
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of JOP20190008A1 publication Critical patent/JOP20190008A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

يتعلق الكشف بطرق علاج أو منع اضطراب نوم عن طريق إعطاء مركب له الصيغة (1)<strong><img src="file:///C:\Users\mohammad.tw\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif" /></strong> (1)، أو مركب له الصيغة (1A)، (1B)، (1C)، (1D)، (1E)، أو (1F) إلى حيوان في حاجة إلى هذا العلاج. في تجسيدات معينة، تعالج أو تمنع تلك المركبات بفعالية اضطراب نوم لدى الحيوان، مع إنتاج آثار جانبية منخفضة مقارنة بمركبات متاحة مسبقًا.
JOP/2019/0008A 2016-07-26 2017-06-16 علاج ومنع اضطرابات النوم JOP20190008A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662366960P 2016-07-26 2016-07-26
US201762536097P 2017-07-24 2017-07-24
PCT/IB2017/054506 WO2018020418A1 (en) 2016-07-26 2017-07-25 Treatment and prevention of sleep disorders

Publications (1)

Publication Number Publication Date
JOP20190008A1 true JOP20190008A1 (ar) 2019-01-24

Family

ID=59714072

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0008A JOP20190008A1 (ar) 2016-07-26 2017-06-16 علاج ومنع اضطرابات النوم

Country Status (20)

Country Link
US (3) US10974081B2 (ar)
EP (1) EP3490563A1 (ar)
JP (2) JP7198197B2 (ar)
KR (2) KR102531366B1 (ar)
CN (1) CN109689058B (ar)
AU (2) AU2017304898B2 (ar)
BR (1) BR112019001457A2 (ar)
CA (1) CA3031388C (ar)
CL (1) CL2019000190A1 (ar)
EC (1) ECSP19014247A (ar)
IL (1) IL264294B (ar)
JO (1) JOP20190008A1 (ar)
MX (1) MX2019001036A (ar)
NZ (1) NZ750817A (ar)
PH (1) PH12019500177A1 (ar)
SG (1) SG11201900486WA (ar)
TN (1) TN2019000019A1 (ar)
TW (1) TWI661827B (ar)
WO (1) WO2018020418A1 (ar)
ZA (1) ZA201901055B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
EP3743049A1 (en) * 2018-01-24 2020-12-02 Purdue Pharma LP Sleep disorder treatment and prevention
KR102198846B1 (ko) * 2018-06-29 2021-01-05 다인기술 주식회사 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체
US11547350B2 (en) 2018-12-26 2023-01-10 Industrial Technology Research Institute Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium
CN111359074B (zh) * 2018-12-26 2022-08-02 财团法人工业技术研究院 个人化参数学习方法、睡眠辅助装置及存储介质
MX2021008039A (es) * 2019-01-31 2021-08-05 Purdue Pharma Lp Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido.
US20220331303A1 (en) * 2019-09-13 2022-10-20 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
EP1491212B1 (en) * 2002-03-29 2012-08-08 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
EP1620075B1 (en) 2003-05-07 2020-06-24 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
US8067603B2 (en) 2003-09-25 2011-11-29 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
WO2006025267A1 (ja) * 2004-08-31 2006-03-09 Mitsubishi Pharma Corporation Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
TWI448289B (zh) * 2007-08-31 2014-08-11 Purdue Pharma Lp 經取代之喹啉型哌啶化合物及其用途
CL2009000557A1 (es) 2008-03-11 2010-10-01 Takeda Pharmaceuticals Co Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos
UA99540C2 (ru) * 2008-07-21 2012-08-27 Пердью Фарма Л.П. Замещенные мостиковым хиноксалином пиперидиновые соединения и их применение
EP2797912B1 (en) 2011-12-01 2016-05-25 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
WO2014102590A1 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102592A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم

Also Published As

Publication number Publication date
CA3031388A1 (en) 2018-02-01
NZ750817A (en) 2020-07-31
EP3490563A1 (en) 2019-06-05
US11738023B2 (en) 2023-08-29
CA3031388C (en) 2023-02-14
KR102210209B1 (ko) 2021-02-01
JP7291172B2 (ja) 2023-06-14
ECSP19014247A (es) 2019-05-31
IL264294B (en) 2022-06-01
SG11201900486WA (en) 2019-02-27
US20190282836A1 (en) 2019-09-19
JP2021120379A (ja) 2021-08-19
CL2019000190A1 (es) 2019-06-07
KR20210013319A (ko) 2021-02-03
AU2017304898B2 (en) 2020-08-20
ZA201901055B (en) 2019-12-18
TW201817423A (zh) 2018-05-16
CN109689058A (zh) 2019-04-26
MX2019001036A (es) 2019-06-10
AU2020273332B2 (en) 2022-11-24
AU2017304898A1 (en) 2019-03-07
US10974081B2 (en) 2021-04-13
JP2019523269A (ja) 2019-08-22
US20210330994A1 (en) 2021-10-28
IL264294A (en) 2019-02-28
PH12019500177A1 (en) 2019-10-14
TWI661827B (zh) 2019-06-11
JP7198197B2 (ja) 2022-12-28
CN109689058B (zh) 2022-03-22
WO2018020418A1 (en) 2018-02-01
KR102531366B1 (ko) 2023-05-12
TN2019000019A1 (en) 2020-07-15
BR112019001457A2 (pt) 2019-05-07
US20240058333A1 (en) 2024-02-22
KR20190029682A (ko) 2019-03-20
AU2020273332A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
JOP20190008A1 (ar) علاج ومنع اضطرابات النوم
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201690745A1 (ru) Способы лечения и предотвращения болезни &#34;трансплантат против хозяина&#34;
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2022009736A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
MX2016008119A (es) Uso de derivados de isoxazolina para el tratamiento o prevencion de infestaciones por artropodos en aves de corral.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2019000413A (es) Inhibidores de triptofano 2,3-dioxigenasa.